Mga Batayang Estadistika
| CIK | 1235912 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CVRx, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 5, 2025 |
Seventh Amendment to Lease, dated May 20, 2025, by and between the Company and TCI TT, LLC Exhibit 10.1 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (“Amendment”) is dated May 20th, 2025 (“Effective Date”), by and between TCI TT, LLC, a Delaware limited liability company (“Landlord”), and CVRx, Inc., a Delaware corporation (“Tenant”). A.Landlord, as successor in interest to Duke Realty Limited Partnership, and Tenant are the current parties to that certain Lease dated Octo |
|
| August 4, 2025 |
CVRx, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share data) Exhibit 99.1 CVRx Reports Second Quarter 2025 Financial and Operating Results MINNEAPOLIS, August 4, 2025 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2025 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2025 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40545 (Commission File Number) 41-1983744 (I.R.S. Employer Identification No.) 9201 West Broadway Avenue, Suite 650 Minneapolis, MN (Address of principal executive |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| May 8, 2025 |
CVRx Reports First Quarter 2025 Financial and Operating Results Exhibit 99.1 CVRx Reports First Quarter 2025 Financial and Operating Results MINNEAPOLIS, May 8, 2025 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the firs |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 7, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 7, 2025 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 7, 2025 |
Exhibit 99.1 CVRx Reports Preliminary First Quarter 2025 Financial Results First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024 MINNEAPOLIS, April 7, 2025 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 reve |
|
| February 20, 2025 |
EXHIBIT 2 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable |
|
| February 20, 2025 |
EX-1 2 exh1.htm AGREEMENT REGARDING FILING OF JOINT SCHEDULE 13D EXHIBIT 1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of CVRx, Inc. EXECUTED this 20th day of February |
|
| February 18, 2025 |
As filed with the Securities and Exchange Commission on February 18, 2025 As filed with the Securities and Exchange Commission on February 18, 2025 Registration No. |
|
| February 18, 2025 |
Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of CVRx, Inc., hereby severally constitute and appoint Kevin Hykes and Jared Oasheim, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in an |
|
| February 18, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CVRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per sha |
|
| February 18, 2025 |
CVRx, Inc. Insider Trading Policy Exhibit 19.1 CVRx, INC. INSIDER TRADING POLICY Purpose Federal and state securities laws prohibit individuals from trading in the securities of a company while they are aware of material information about that company that is not generally known or available to the public. Such trading is often referred to as “insider trading.” The purpose of this Insider Trading Policy is to prevent insider tradi |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| February 4, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 4, 2025 |
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results Exhibit 99.1 CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results MINNEAPOLIS, Feb. 4, 2025 (GLOBE NEWSWIRE) - CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fou |
|
| January 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 13, 2025 |
Exhibit 99.1 CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance · Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35% · Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30% · Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, repre |
|
| November 7, 2024 |
SC 13D/A 1 nea10-cvrx18897.htm NEW ENTERPRISE ASSOCIATES 10 LP - CVRX, INC. 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CVRx, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 126638105 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Green |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 1, 2024 |
CVRX / CVRx, Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment SC 13G/A 1 s13ga093024-cvrx.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 CVRx, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securi |
|
| November 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 29, 2024 |
CVRx Reports Third Quarter 2024 Financial and Operating Results Exhibit 99.1 CVRx Reports Third Quarter 2024 Financial and Operating Results MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the th |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 27, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 29, 2024 |
CVRx Reports Second Quarter 2024 Financial and Operating Results Exhibit 99.1 CVRx Reports Second Quarter 2024 Financial and Operating Results MINNEAPOLIS, July 29, 2024 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the s |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 7, 2024 |
Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF CVRx, INC. CVRx, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: 1. The name of the Corporation is CVRx, Inc., and the Corporation’s original Certificate of Incorporation was filed with the Secretary of State on Aug |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40545 (Commission file number) 9201 West Broadway Avenue, Suite 650 Minneapolis, MN (Address of principal executive offices) 55445 (Zip code) Jared Oasheim Chief Fi |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 30, 2024 |
CVRx Reports First Quarter 2024 Financial and Operating Results Exhibit 99.1 CVRx Reports First Quarter 2024 Financial and Operating Results MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the f |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of CVRx, Inc., hereby severally constitute and appoint Nadim Yared and Jared Oasheim, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in an |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 9, 2024 |
Exhibit 24.1 POWER OF ATTORNEY We, the undersigned officers and directors of CVRx, Inc., hereby severally constitute and appoint Nadim Yared and Jared Oasheim, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in an |
|
| February 9, 2024 |
CVRx, Inc. Mandatory Compensation Recovery Policy Exhibit 97.1 CVRx, INC. MANDATORY COMPENSATION RECOVERY POLICY Policy The Board of Directors (the “Board”) of CVRx, Inc. (the “Company”) has adopted this Mandatory Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Securities and Exchange Commission (“SEC”) regulations promulgated thereunder, and applicab |
|
| February 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CVRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per sha |
|
| February 9, 2024 |
Exhibit 10.1 CVRx, Inc. Stock Option Agreement (Inducement Grant) CVRx, Inc. (the “Company”), hereby grants an Option to purchase shares of the Company’s common stock to you, the Participant named below. The terms and conditions of this Option Award are set forth in this Agreement, consisting of this cover page and the Option Terms and Conditions on the following pages. This Option Award is made a |
|
| February 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CVRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per share |
|
| February 9, 2024 |
As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. |
|
| February 9, 2024 |
Sixth Amendment to Lease, dated November 7, 2023 by and between the Company and TCI TT, LLC Exhibit 10.7 SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (“Amendment”) is dated this 7th day of November, 2023, by and between TCI TT, LLC, a Delaware limited liability company (“Landlord”), and CVRx, Inc., a Delaware corporation (“Tenant”). A.Landlord, as successor in interest to Duke Realty Limited Partnership, and Tenant are the current parties to that certain Lease dated October 13, |
|
| February 6, 2024 |
CVRX / CVRx, Inc. / Vensana Capital I GP, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* CVRx, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 126638105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 2, 2024 |
CVRX / CVRx, Inc. / JOHNSON & JOHNSON - SCHEDULE 13G/A Passive Investment SC 13G/A 1 s13ga123123-cvrx.htm SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 CVRx, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securi |
|
| January 31, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into effective January 26, 2024, by and between CVRx, Inc., a Delaware corporation (the “Company”), and Kevin Hykes (“Executive”). WHEREAS, the Company desires to employ and Executive desires to accept employment with the Company, on the terms and conditions set forth in this Agreement; WHEREAS, the Company w |
|
| January 31, 2024 |
Exhibit 10.2 TRANSITION AND CONSULTING AGREEMENT This TRANSITION AND CONSULTING AGREEMENT (the “Agreement”), dated January 30, 2024, is entered into by and between CVRx, Inc., a Delaware corporation (the “Company”), and Nadim Yared (the “Executive”). RECITALS WHEREAS, Executive is currently employed by the Company as the Company’s President and Chief Executive Officer. WHEREAS, the Company and Exe |
|
| January 31, 2024 |
CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer Exhibit 99.1 CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer · Appointment effective February 12 following Nadim Yared’s retirement · Hykes currently serves as Augmedics’ President and CEO, and has served on CVRx’s Board of Directors since 2022 MINNEAPOLIS, January 31, 2024 – CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced |
|
| January 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 25, 2024 |
CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results Exhibit 99.1 CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results MINNEAPOLIS, January 25, 2024 (GLOBE NEWSWIRE) - CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the |
|
| January 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 19, 2024 |
CVRX / CVRx, Inc. / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* CVRx, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 126638105 (CUSIP number) Edwin de Graaf Cooperatieve Gilde |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2024 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 8, 2024 |
Exhibit 99.1 CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results and Announces Nadim Yared Retirement Plans · Fourth quarter revenue expected to be $11.2 million to $11.3 million, representing growth of 56% to 58% · Full year revenue expected to be $39.2 million to $39.3 million, representing growth of 74% to 75% · President and CEO Nadim Yared plans to retire upon the c |
|
| December 29, 2023 |
CVRX / CVRx, Inc. / Cooperatieve Gilde Healthcare IV U.A. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* CVRx, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 126638105 (CUSIP number) Edwin de Graaf Cooperatieve Gilde |
|
| December 29, 2023 |
EX-99.1 2 d484532dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge t |
|
| December 26, 2023 |
Exhibit 99.1 CVRx receives FDA approval for expanded labeling of Barostim U.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF data MINNEAPOLIS, Dec 26, 2023 – CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has approved revised Instructions For Use (IF |
|
| December 26, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 26, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| October 26, 2023 |
CVRx Reports Third Quarter 2023 Financial and Operating Results Exhibit 99.1 CVRx Reports Third Quarter 2023 Financial and Operating Results MINNEAPOLIS, Oct. 26, 2023 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the th |
|
| October 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 25, 2023 |
CVRx Reports Second Quarter 2023 Financial and Operating Results Exhibit 99.1 CVRx Reports Second Quarter 2023 Financial and Operating Results MINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the s |
|
| June 8, 2023 |
Exhibit 99.1 43rd Annual William Blair Growth Stock Conference, June 2023 2 Cautionary Note Regarding Forward-Looking Statement This presentation by CVRx, Inc. (the “Company”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements re |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40545 (Commission file number) 9201 West Broadway Avenue, Suite 650 Minneapolis, MN (Address of principal executive offices) 55445 (Zip code) Jared Oasheim Chief Fi |
|
| May 11, 2023 |
Exhibit 10.1 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (“Amendment”) is dated April 21, 2023, by and between TCI TT, LLC, a Delaware limited liability company (“Landlord”), and CVRx, Inc., a Delaware limited liability company (“Tenant”). A.Landlord, as successor in interest to Duke Realty Limited Partnership, and Tenant are the current parties to that certain Lease dated October 13, 2 |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 27, 2023 |
CVRx Reports First Quarter 2023 Financial and Operating Results Exhibit 99.1 CVRx Reports First Quarter 2023 Financial and Operating Results MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the f |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 21, 2023 |
DEF 14A 1 tm232035d1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Comm |
|
| March 21, 2023 |
Exhibit 99.2 March 21, 2023 Preliminary Results of the Post-Market Phase of the BeAT-HF Randomized Clinical Trial 2 Forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including statements regarding our fut |
|
| March 21, 2023 |
Exhibit 99.1 Totality of Evidence from BeAT-HF Study Shows CVRx’s Barostim Provides Long-term Benefits for Patients with Heart Failure MINNEAPOLIS, Mar. 21, 2023 – CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovas |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 21, 2023 |
CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial Exhibit 99.1 CVRx Reports Preliminary Results of the BeAT-HF Post-Market Randomized Clinical Trial The trial did not meet its primary endpoint, however, the totality of data supports Barostim’s use as an effective treatment for patients with heart failure MINNEAPOLIS, February 21, 2023 (GLOBE NEWSWIRE) - CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufact |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 21, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 14, 2023 |
CVRX / CVRx, Inc. / Soleus Capital Master Fund, L.P. - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CVRx, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 126638105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| February 10, 2023 |
As filed with the Securities and Exchange Commission on February 10, 2023 As filed with the Securities and Exchange Commission on February 10, 2023 Registration No. |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40 |
|
| February 10, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CVRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per sha |
|
| February 6, 2023 |
CVRX / CVRx, Inc. / GLAXOSMITHKLINE PLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1- Exit Filing)* CVRx, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) December 31, 2022 126638 10 5 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 3, 2023 |
CVRX / CVRx, Inc. / Vensana Capital I GP, LLC - SC 13G/A Passive Investment SC 13G/A 1 d392086dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CVRx, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 126638105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropr |
|
| January 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 26, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 26, 2023 |
Exhibit 99.1 CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results Fourth Quarter 2022 Revenue of $7.2 million, a 96% Increase Over Prior Year MINNEAPOLIS, January 26, 2023 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patient |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 9, 2023 |
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results MINNEAPOLIS, January 9, 2023 (GLOBE NEWSWIRE) - CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarter |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 15, 2022 |
Piper Sandler November 15, 2022 TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ??Registration No. 333-268183? PROSPECTUS SUPPLEMENT $50,000,000? Common Stock ? We have entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, as our sales agent, relating to the sale of shares of our common stock, $0.01 par value per share, offered by this prospectus sup |
|
| November 15, 2022 |
EX-FILING FEES 2 tm2229612d6ex-filingfees.htm EX-FILING FEES Exhibit 107 The prospectus to which this Exhibit 107 is attached is a final prospectus for the related offering. The maximum aggregate offering price for such offering is $50,000,000. |
|
| November 10, 2022 |
CVRx, Inc. 9201 West Broadway Avenue Suite 650 Minneapolis, Minnesota 55445 CVRx, Inc. 9201 West Broadway Avenue Suite 650 Minneapolis, Minnesota 55445 November 10, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CVRx, Inc. Registration Statement on Form S-3 File No. 333-268183 Ladies and Gentlemen: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securi |
|
| November 4, 2022 |
Exhibit 4.3 CVRx, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment of Term |
|
| November 4, 2022 |
As filed with the Securities and Exchange Commission on November 4, 2022 S-3 1 tm2229612-1s3.htm S-3 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 4, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpora |
|
| November 4, 2022 |
Exhibit 1.2 Execution Version CVRX, INC. EQUITY DISTRIBUTION AGREEMENT November 4, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), CVRx, Inc., a company organized under the laws of Delaware (the “Company”), proposes to issue and sell from time to time through Piper Sandler & |
|
| November 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) CVRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 1, 2022 |
Exhibit 99.1 CVRx Reports Third Quarter 2022 Financial and Operating Results Third quarter 2022 revenue of $6.2 million, an 82% increase over prior year MINNEAPOLIS, November 1, 2022 (GLOBE NEWSWIRE) - CVRx, Inc. (?CVRx?), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases |
|
| November 1, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this ?Agreement?) dated as of October 31, 2022 (the ?Effective Date?) among INNOVATUS LIFE SCIENCES LENDING FUND I, LP, a Delaware limited partnership, as collateral agent (in such capacity, together with its successors and assigns in such ca |
|
| November 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):October 31, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):July 28, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 28, 2022 |
Exhibit 99.1 CVRx Reports Second Quarter 2022 Financial and Operating Results Second quarter 2022 revenue of $5.0 million, a 61% increase over prior year MINNEAPOLIS, July 28, 2022 (GLOBE NEWSWIRE) - CVRx, Inc. (?CVRx?), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):June 7, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2022 |
EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Mr. Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments t |
|
| April 29, 2022 |
CVRX / CVRx, Inc. / Soleus Capital Master Fund, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CVRx, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 126638105 (CUSIP Number) April 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| April 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 25, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 25, 2022 |
Exhibit 99.1 CVRx Reports First Quarter 2022 Financial and Operating Results First Quarter 2022 Revenue of $4.1 million, a 43% Increase Over Prior Year MINNEAPOLIS, April 25, 2022 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (?CVRx?), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascu |
|
| April 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 22, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) CVRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.01 per sha |
|
| February 22, 2022 |
As filed with the Securities and Exchange Commission on February 22, 2022 As filed with the Securities and Exchange Commission on February 22, 2022 Registration No. |
|
| February 22, 2022 |
? Exhibit 10.14 CVRx, INC. EMPLOYEE STOCK PURCHASE PLAN ? ? 1.Purpose of the Plan. The purpose of this CVRx, Inc. Employee Stock Purchase Plan (the ?Plan?) is to provide the employees of CVRx, Inc. (the ?Company?) and its participating subsidiaries with a convenient means of purchasing shares of the Company?s common stock from time to time at a discount to market prices through the use of payroll |
|
| February 22, 2022 |
Exhibit 21.1 ? CVRx, Inc. List of Subsidiaries ? ? Name of Company ? State or Other Jurisdiction of Incorporation/Organization CVRx Switzerland LLC ? Switzerland ? |
|
| February 22, 2022 |
? Exhibit 4.16 DESCRIPTION OF THE COMPANY?S COMMON STOCK ? The common stock of CVRx, Inc. (?we,? ?our,? or ?us?) is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following is a description of the material terms of our common stock. The description is qualified in its entirety by reference to our amended and restated certificate of |
|
| February 15, 2022 |
Exhibit 99.1 CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year MINNEAPOLIS, February 15, 2022 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with c |
|
| February 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 15, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 10, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| February 10, 2022 |
POWER OF ATTORNEY March 18, 2021 Exhibit 2 POWER OF ATTORNEY March 18, 2021 Each of the undersigned, including (i) Vensana Capital I GP, LLC, a Delaware limited liability company (the ?Fund I GP?), in the normal course of its business and in its capacity as the general partner of Vensana Capital I, L. |
|
| February 10, 2022 |
CVRX / CVRx, Inc. / Vensana Capital I GP, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CVRx, INC. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 126638105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 7, 2022 |
CVRX / CVRx, Inc. / JOHNSON & JOHNSON - SCHEDULE 13G FOR CVRX, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 CVRx, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 126638105 (CUSIP Number) December 31, 2021 |
|
| January 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 10, 2022 |
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results Exhibit 99.1 CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results MINNEAPOLIS, January 10, 2022 (GLOBE NEWSWIRE) - CVRx, Inc. (?CVRx?), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced certain preliminary unaudited fourth quarte |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2021 |
Exhibit 99.1 CVRx Reports Third Quarter 2021 Financial and Operating Results Third Quarter 2021 Revenue of $3.4 million, a 241% Increase Over Prior Year MINNEAPOLIS, November 4, 2021 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (?CVRx?), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2021 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2021 |
Exhibit 99.1 CVRx Reports Second Quarter 2021 Financial and Operating Results Second Quarter 2021 Revenue of $3.1 million, a 150% Increase Over Prior Year MINNEAPOLIS, August 4, 2021 (GLOBE NEWSWIRE) - CVRx, Inc. (NASDAQ: CVRX) (?CVRx?), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for |
|
| August 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2021 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 15, 2021 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CVRx, Inc. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 126638105 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4000 (Name, Addre |
|
| July 12, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| July 12, 2021 |
CVRX / CVRx, Inc. / Cooperatieve Gilde Healthcare IV U.A. - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* CVRx, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 126638105 (CUSIP number) M.O.J.M. Perret Cooperatieve Gilde He |
|
| July 12, 2021 |
8-K 1 tm2121840d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 9, 2021 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorpora |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CVRx, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) July 2, 2021 126638 10 5 (CUSIP Number) (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| July 7, 2021 |
Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF CVRx, INC. (Adopted effective July 2, 2021) Incorporated under the Laws of the State of Delaware ARTICLE I OFFICES AND RECORDS SECTION 1.1. Delaware Office. The name and address of the Corporation?s registered office in the State of Delaware shall be Corporation Trust Company, 1209 Orange Street in the City of Wilmington, County of New Castle, State of D |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 2, 2021 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40545 41-1983744 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| July 7, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CVRx, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) CVRx, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: That the Corporation was originally incorporated on August 17, 2000, |
|
| July 1, 2021 |
Exhibit 10.5 Officer/Employee Form CVRx, Inc. Non-Qualified Stock Option Agreement Under the 2021 Equity Incentive Plan CVRx, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), hereby grants an Option to purchase shares of the Company?s common stock to you, the Participant named below. The terms and conditions of the Option Award are set forth in this Agreement, consist |
|
| July 1, 2021 |
EXHIBIT 10.7 CVRx, INC. DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT ([Director name]) THIS AGREEMENT, made as of [GRANT DATE] by and between CVRx, Inc., a Delaware corporation (the ?Company?), and [DIRECTOR?S FIRM] (?Optionee?). WHEREAS, the Company wishes to grant this stock option to Optionee in lieu of granting a stock option to [Director] (the ?Director?) in consideration for the Director?s |
|
| July 1, 2021 |
PROSPECTUS 7,000,000 Shares Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(4)? ?Registration No. 333-256800? PROSPECTUS 7,000,000 Shares Common Stock ? This is CVRx, Inc.?s initial public offering. We are selling 7,000,000 shares of our common stock. Prior to this offering, no public market existed for the shares. Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol ?CVRX.? We |
|
| July 1, 2021 |
Exhibit 10.6 Non-Employee Director Form CVRx, Inc. Non-Qualified Stock Option Agreement Under the 2021 Equity Incentive Plan CVRx, Inc. (the ?Company?), pursuant to its 2021 Equity Incentive Plan (the ?Plan?), hereby grants an Option to purchase shares of the Company?s common stock to you, the Participant named below. The terms and conditions of the Option Award are set forth in this Agreement, co |
|
| July 1, 2021 |
Form S-8 (File No. 333-257616) As filed with the Securities and Exchange Commission on July 1, 2021 Registration No. |
|
| July 1, 2021 |
EXHIBIT 10.3 CVRx, INC. DIRECTOR NON-QUALIFIED STOCK OPTION AGREEMENT THIS AGREEMENT, made as of [grant date] by and between CVRx, Inc., a Delaware corporation (the ?Company?), and [Director] (?Optionee?). WHEREAS, the Company, pursuant to the CVRx, Inc. 2001 Stock Option Plan (the ?Plan?), as administered by the Board of Directors of the Company (the ?Board?), wishes to grant this stock option to |
|
| July 1, 2021 |
exhibit 10.2 CVRx, INC. [OFFICER][EMPLOYEE] [INCENTIVE][NON-QUALIFIED] STOCK OPTION AGREEMENT Summary of Terms Optionee: Date of grant: Number of shares subject to Option: Exercise price per Share: Vesting Schedule: Date Vesting By signing below, the parties agree to the terms of the Option as set forth in this Summary of Terms and the attached Employee [Incentive][Non-Qualified] Stock Option Agre |
|
| June 29, 2021 |
As filed with the Securities and Exchange Commission on June 29, 2021. As filed with the Securities and Exchange Commission on June 29, 2021. Registration No. 333-??????????? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standar |
|
| June 25, 2021 |
CVRx, Inc. 9201 West Broadway Avenue, Suite 650 Minneapolis, MN 55445 CVRx, Inc. 9201 West Broadway Avenue, Suite 650 Minneapolis, MN 55445 June 25, 2021 VIA EDGAR TRANSMISSION Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ibolya Ignat Jeanne Baker Kasey Robinson Jeffrey Gabor Re: CVRx, Inc. Registration Statement on Form S-1 (Registration No. 333-256800) |
|
| June 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CVRx, Inc. (Exact name of registrant as specified in its charter) Delaware 41-1983744 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 9201 West Broa |
|
| June 25, 2021 |
June 25, 2021 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 23, 2021 |
Form of Employee Stock Purchase Plan. Exhibit 10.10 CVRx, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose of the Plan. The purpose of this CVRx, Inc. Employee Stock Purchase Plan (the ?Plan?) is to provide the employees of CVRx, Inc. (the ?Company?) and its participating subsidiaries with a convenient means of purchasing shares of the Company?s common stock from time to time at a discount to market prices through the use of payroll deduc |
|
| June 23, 2021 |
Exhibit 10.9 CVRx, Inc. 2021 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to assist the Company in attracting, retaining, motivating and rewarding certain key employees, officers, directors, and consultants of the Company and its Affiliates, promoting the creation of long-term value for stockholders of the Company by closely aligning the interests of such individuals with those of |
|
| June 23, 2021 |
Exhibit 4.2 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE SIDE FOR CERTAIN DEFINITIONSCUSIP 126638 10 5THIS CERTIFIES THATis the owner ofFULLY PAID AND NON-ASSESSABLE COMMON SHARES, $0.01 PAR VALUE, OF CVRx, Inc. transferable on the books of the Corporation by the holder hereof in person or by Attorney upon surrender of this certificate properly endorsed. This certificate is not |
|
| June 23, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT CVRx, Inc. [?] Shares of Common Stock Underwriting Agreement [?], 2021 J.P. Morgan Securities LLC Piper Sandler & Co. William Blair & Company, L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Piper Sandler & Co. 345 Park Avenue, Suite 1200 New York, New |
|
| June 23, 2021 |
Exhibit 10.12 [AMENDED AND RESTATED] EMPLOYMENT AGREEMENT THIS [AMENDED AND RESTATED] EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into effective June , 2021, by and between CVRx, Inc., a Delaware corporation (the ?Company?), and [Executive Name] (?Executive?). [WHEREAS, the Company and Executive are parties to an employment agreement dated as of [Date] setting forth certain terms of employm |
|
| June 23, 2021 |
Exhibit 10.13 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this ?Agreement?) is made and entered into as of [], 20[] between CVRx, Inc., a Delaware corporation (the ?Company?), and [Name] (?Indemnitee?). WITNESSETH THAT: WHEREAS, it is essential that the Company retain and attract as directors and officers the most capable persons available; WHEREAS, the Certificate of Incorporation o |
|
| June 23, 2021 |
Form of Amended and Restated Bylaws to be in effect upon the closing of this offering. Exhibit 3.5 AMENDED AND RESTATED BY-LAWS OF CVRx, INC. (Adopted effective , 2021) Incorporated under the Laws of the State of Delaware ARTICLE I OFFICES AND RECORDS SECTION 1.1. Delaware Office. The name and address of the Corporation?s registered office in the State of Delaware shall be Corporation Trust Company, 1209 Orange Street in the City of Wilmington, County of New Castle, State of Delawar |
|
| June 23, 2021 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE TWELFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CVRX, INC. CVRx, Inc. (hereinafter referred to as the ?Corporation?), a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify: 1. The name of the Corporation is CVRx, Inc., which is the name under which the Corporation wa |
|
| June 23, 2021 |
Form S-1, as amended (File No. 333-256800 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 23, 2021. |
|
| June 23, 2021 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CVRx, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) CVRx, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: That the Corporation was originally incorporated on August 17, 2000, |
|
| June 22, 2021 |
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED BY CVRx, INC. Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By Secured Electronic Transmission and EDGAR June 17, 2021 FOIA Confidential Treatment Request Under 17 C.F.R. ?200.83 Ibolya Ignat Jeanne Baker Kasey Robinson Jeffrey Gabor U.S. Securities and Exchange Commission Division of Corporation Finance Offic |
|
| June 4, 2021 |
Exhibit 10.4 LEASE AMENDING AGREEMENT NO. 3 This LEASE AMENDING AGREEMENT NO. 3 (this "Amendment") is dated April 21, 2016, for reference purposes only, by CVRx, Inc., a Delaware corporation ("Tenant") and AX CROSSTOWN VI L.P. ("Landlord"), with reference to the following facts: A. Landlord, as successor in title to DUKE REALTY LIMITED PARTNERSHIP, and Tenant are the current parties to that certai |
|
| June 4, 2021 |
Amended and Restated Bylaws, as amended, as currently in effect. Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF CVRX, INC. ARTICLE I. OFFICES, CORPORATE SEAL Section 1.01. Registered Office. The registered office of the corporation in Delaware shall be that set forth in the certificate of incorporation or in the most recent amendment to the certificate of incorporation or resolution of the directors filed with the secretary of state of Delaware changing the registe |
|
| June 4, 2021 |
Exhibit 4.15 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A |
|
| June 4, 2021 |
Exhibit 4.11 THE SECURITIES EVIDENCED HEREBY and the SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER EITHER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR APPLICABLE BLUE SKY LAWS AND MAY BE OFFERED, SOLD AND TRANSFERRED ONLY IF REGISTERED AND QUALIFIED PURSUANT TO THE ACT AND RELEVANT STATE SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL OR OTHER EVIDENCE |
|
| June 4, 2021 |
Exhibit 10.8 [As amended and restated] CVRx, INC. 2001 STOCK INCENTIVE PLAN Section 1.????Purpose of the Plan. This Plan shall be known as the ?CVRx, Inc. 2001 Stock Incentive Plan? and is hereinafter referred to as the ?Plan.? The purpose of this Plan is to promote the interests of the Company and its stockholders by aiding in maintaining and developing employees, officers, consultants, independe |
|
| June 4, 2021 |
1 BOS 48031695v2 BOS 48045966v1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| June 4, 2021 |
Exhibit 4.5 |
|
| June 4, 2021 |
Exhibit 4.12 THE SECURITIES EVIDENCED HEREBY and the SECURITIES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER EITHER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR APPLICABLE BLUE SKY LAWS AND MAY BE OFFERED, SOLD AND TRANSFERRED ONLY IF REGISTERED AND QUALIFIED PURSUANT TO THE ACT AND RELEVANT STATE SECURITIES LAWS OR IF THE COMPANY IS PROVIDED AN OPINION OF COUNSEL OR OTHER EVIDENCE |
|
| June 4, 2021 |
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| June 4, 2021 |
Exhibit 4.6 |
|
| June 4, 2021 |
1 BOS 48031695v2 BOS 48045974v1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| June 4, 2021 |
1 BOS 48031695v2 BOS 48045972v1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| June 4, 2021 |
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HA VE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| June 4, 2021 |
Exhibit 10.3 Exhibit 10.3 |
|
| June 4, 2021 |
Exhibit 10.11 VENTURE LOAN AND SECURITY AGREEMENT Dated as of September 30, 2019 by and among HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation 312 Farmington Avenue Farmington, CT 06032 as a Lender and Collateral Agent And CVRx, INC., a Delaware corporation 9201 W. Broadway Ave., #650 Minneapolis, MN 55445 as Borrower Loan A Commitment Amount: $5,000,000 Loan B Commitment Amount: $5, |
|
| June 4, 2021 |
Exhibit 10.6 EIGHTH AMENDED AND RESTATED VOTING AGREEMENT This EIGHTH AMENDED AND RESTATED Voting Agreement (this ?Agreement?) is made as of the 1st day of July, 2020 (the ?Effective Date?), by and among CVRx, Inc., a Delaware corporation (the ?Company?), and the holders of Series A-2 Preferred Stock (as defined below) listed on Schedule A hereto (the ?Series A Purchasers?), the holders of Series |
|
| June 4, 2021 |
Exhibit 4.16 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A |
|
| June 4, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 4, 2021. |
|
| June 4, 2021 |
Exhibit 10.5 US.106130059.03 LEASE AMENDING AGREEMENT NO. 4 This LEASE AMENDING AGREEMENT NO. 4 (this "Amendment") is dated May 18, 2020, for reference purposes only, by CVRx, Inc., a Delaware corporation ("Tenant") and AX CROSSTOWN VI L.P. ("Landlord"), with reference to the following facts: A. Landlord, as successor in title to DUKE REALTY LIMITED PARTNERSHIP, and Tenant are the current parties |
|
| June 4, 2021 |
Exhibit 10.1 Exhibit 10.1 -21- IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the day and year first above written. LANDLORD: DUKE REALTY LIMITED PARTNERSHIP, an Indiana limited partnership By: Duke Realty Corporation, its General Partner By: /s/ Patrick E. Mascia Patrick E. Mascia Senior Vice President STATE OF ) ) SS: COUNTY OF ) Before me, a Notary Public in and for said |
|
| June 4, 2021 |
Exhibit 4.13 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A |
|
| June 4, 2021 |
Exhibit 4.14 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) EFFECTIVE REGISTRATION STATEMENTS RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATIONS ARE NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE A |
|
| June 4, 2021 |
Exhibit 21.1 CVRx, Inc. List of Subsidiaries Name of Company State or Other Jurisdiction of Incorporation/Organization CVRx Switzerland LLC Switzerland |
|
| June 4, 2021 |
Exhibit 10.2 Exhibit 10.2 -7- IN WITNESS WHEREOF, the parties have caused this Amendment to be executed on the day and year first written above. LANDLORD: DUKE REALTY LIMITED PARTNERSHIP, an Indiana limited partnership By: Duke Realty Corporation, its general partner Dated: 11/30/10 By: /s/ Patrick E. Mascia Patrick E. Mascia Senior Vice President STATE OF ) ) SS: COUNTY OF ) Before me, a Notary P |
|
| June 4, 2021 |
Exhibit 10.7 CVRx, INC. EIGHTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS EIGHTH AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of the 1st day of July, 2020, by and among CVRx, Inc., a Delaware corporation (the ?Company?), and (a) each of the holders of Series A-2 Convertible Preferred Stock of the Company, listed on Schedule A, (b) each |
|
| June 4, 2021 |
1 BOS 48031695v2 BOS 48045969v1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5. |
|
| June 4, 2021 |
Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR June 4, 2021 Ibolya Ignat Jeanne Baker Kasey Robinson Jeffrey Gabor U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: CVRx, Inc. Amendment No. 1 to Draft |
|
| June 4, 2021 |
Twelfth Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 TWELFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CVRX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) CVRx, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: That the Corporation was ori |
|
| May 14, 2021 |
DRS/A 1 filename1.htm TABLE OF CONTENTS Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on May 14, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washingto |
|
| May 14, 2021 |
Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax By EDGAR May 14, 2021 Ibolya Ignat Jeanne Baker Kasey Robinson Jeffrey Gabor U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Re: CVRx, Inc. Draft Registration Statem |
|
| April 9, 2021 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on April 9, 2021. |
|
| April 9, 2021 |
DRSLTR 1 filename1.htm Faegre Drinker Biddle & Reath LLP 2200 Wells Fargo Center 90 S. Seventh Street Minneapolis, Minnesota 55402 +1 612 766 7000 main +1 612 766 1600 fax April 9, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: CVRx, Inc. Draft Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of |
